February 21, 2025

Novel Menin Inhibitors Show Safety and Activity in Several Clinical Trials

The recently approved menin inhibitor revumenib is poised to improve the treatment of acute leukemia, specifically for disease with a KMT2A rearrangement. Promising results for other novel menin inhib...

The ASCO Post

February 21, 2025

Study Links Stress to Immune Changes in Breast Cancer

New research shows chronic stressors like perceived stress, inadequate social support, racial discrimination, and neighborhood deprivation are associated with deleterious changes to systemic and tumor immunity in breast cancer patients, with more pronounced effects in Black women.

Conexiant

February 21, 2025

Environmental vs. Genetic Risk in Aging and Mortality

Researchers quantify the exposome's greater impact on aging and mortality risk compared with genetic predisposition, identifying 25 key environmental risk factors.

Conexiant

February 21, 2025

T-DXd Approved by the FDA for Pretreated Patients With HER2-Low or -Ultralow Metastatic Breast Cancer

The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has been approved for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HE...

The ASCO Post

February 21, 2025

Jennifer A. Woyach, MD, Named The Ohio State’s Director of Hematology

Jennifer A. Woyach, MD, a hematology cancer expert and researcher who has been with The Ohio State for more than 12 years, has been named Director of the Division of Hematology at The Ohio State Unive...

The ASCO Post

February 21, 2025

FDA Approves First Cerebrotendinous Xanthomatosis Treatment

The FDA has approved Ctexli (chenodiol) as the first treatment for cerebrotendinous xanthomatosis, a rare lipid storage disorder.

Conexiant

February 21, 2025

Exercise Therapy as Candidate Anticancer Strategy

Lee Jones, PhD, Head of the Exercise Oncology Program at Memorial Sloan Kettering Cancer Center, shared findings from an early-phase clinical trial to determine the feasibility, safety, and tumor biol...

The ASCO Post

February 21, 2025

FDA Ends Semaglutide Shortage, Updates Policy

FDA declares resolution of nationwide semaglutide injection shortage and outlines 60 to 90 day transition periods for compounding facilities while other GLP-1 medications remain in limited supply.

Conexiant

February 21, 2025

Filgotinib Shows Long-Term Safety in RA Patients

Filgotinib was well-tolerated over 8 years in rheumatoid arthritis patients, with low incidences of serious adverse events.

Conexiant